NCT04675333 2025-08-03Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)ALX Oncology Inc.Phase 2 Active not recruiting172 enrolled
NCT04675294 2025-08-01Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)ALX Oncology Inc.Phase 2 Active not recruiting189 enrolled